2025-03-13 02:40:03
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Tatva Chintan Pharma Chem Ltd Q3 FY2024 consolidated net profit declines to Rs. 3.45 crore
Posted On : 2024-01-20 15:34:01( TIMEZONE : IST )
Tatva Chintan Pharma Chem Ltd has reported Consolidated financial results for the period ended December 31, 2023.
Financial Results (Q3 FY2024) - QoQ Comparison
The company has reported total income of Rs. 85.416 crores during the period ended December 31, 2023 as compared to Rs. 97.425 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs. 3.455 crores for the period ended December 31, 2023 as against net profit / (loss) of Rs. 7.781 crores for the period ended September 30, 2023.
The company has reported EPS of Rs. 1.48 for the period ended December 31, 2023 as compared to Rs. 3.43 for the period ended September 30, 2023.
| Financials | Q3 FY2024 | Q2 FY2024 | % Change |
| Total Income | ₹ 85.416 crs | ₹97.425 crs |  -12.33% |
| Net Profit | ₹3.455 crs | ₹7.781 crs | -55.60% |
| EPS | ₹1.48 | ₹3.43 | -56.85% |
Financial Results (Q3 FY2024) - YoY Comparison
The company has reported total income of Rs. 85.416 crores during the period ended December 31, 2023 as compared to Rs.121.684 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs.3.455 crores for the period ended December 31, 2023 as against net profit / (loss) of Rs.11.623 crores for the period ended December 31, 2022.
The company has reported EPS of Rs.1.48 for the period ended December 31, 2023 as compared to Rs.5.24 for the period ended December 31, 2022.
| Financials | Q3 FY2024 | Q3 FY2023 | % Change |
| Total Income | ₹ 85.416 crs | ₹121.684 crs | -29.81% |
| Net Profit | ₹3.455 crs | ₹11.623 crs | -70.27% |
| EPS | ₹1.48 | ₹5.24 | -71.76% |
Financial Results (9 Months Ended FY2024) - YoY Comparison
The company has reported total income of Rs.298.219 crores during the 9 Months period ended December 31, 2023 as compared to Rs.303.999 crores during the 9 Months period ended December 31, 2022.
The company has posted net profit / (loss) of Rs.20.740 crores for the 9 Months period ended December 31, 2023 as against net profit / (loss) of Rs.28.528 crores for the 9 Months period ended December 31, 2022.
The company has reported EPS of Rs.9.13 for the 9 Months period ended December 31, 2023 as compared to Rs.12.87 for the 9 Months period ended December 31, 2022.
| Financials | 9 Months Ended FY2024 | 9 Months Ended FY2023 | % Change |
| Total Income | ₹298.219 crs | ₹303.999 crs | -1.90% |
| Net Profit | ₹20.740 crs | ₹28.528 crs | -27.30% |
| EPS | ₹9.13 | ₹12.87 | -29.06% |
Shares of Tatva Chintan Pharma Chem Ltd was last trading in BSE at Rs. 1466.90 as compared to the previous close of Rs. 1426.55. The total number of shares traded during the day was 3628 in over 626 trades.
The stock hit an intraday high of Rs. 1474.95 and intraday low of 1439.00. The net turnover during the day was Rs. 5287733.00.
